Dianthus Therapeutics
DNTH
91 hedge funds and large institutions have $859M invested in Dianthus Therapeutics in 2024 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 6 closing their positions.
300% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 6
104% more capital inflows, than outflows
Capital inflows: $92M | Capital outflows: $45.1M
60% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 20
23% more funds holding
Funds holding: 74 → 91 (+17)
5.66% more ownership
Funds ownership: 101.2% → 106.86% (+5.7%)
0% more call options, than puts
Call options by funds: $11K | Put options by funds: $11K
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$27.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$11.5M |
| 3 |
Janus Henderson Group
London,
|
+$7.62M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.34M |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$4.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$13.5M |
| 2 |
VA
VR Adviser
New York
|
-$9.75M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.47M |
| 4 |
Vestal Point Capital
New York
|
-$5.71M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$1.73M |
DNTH Hedge Fund Activity: Q3 2024 in Review
91 of the 6,983 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2024, worth a combined $859M — up 12% from $769M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new DNTH positions and 6 closed out — a net gain of 18 holders — while 32 added to existing stakes and 20 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $27.8M. The largest seller was Great Point Partners, cutting an estimated $13.5M.
- 91 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2024, up from 74 in Q2 2024.
- Funds reported $859M of Dianthus Therapeutics stock for Q3 2024, up 12% quarter-over-quarter.
- 24 funds opened new Dianthus Therapeutics positions in Q3 2024 and 6 closed out, a net change of +18 holders.
- The largest Dianthus Therapeutics buyer in Q3 2024 was AllianceBernstein, an estimated $27.8M added.
- The largest Dianthus Therapeutics seller in Q3 2024 was Great Point Partners, an estimated $13.5M sold.
Based on aggregated 13F filings for Q3 2024.